Biotech giant Moderna announced on Monday that it has sealed an agreement with Gavi, a global Vaccine Alliance, aiming to provide approximately 500 million doses of COVID-19 vaccines for the U.N.-backed program.
The UN-backed COVAX program is working towards the provision of coronavirus vaccines for individuals living in low- and middle-income countries by the end of 2022.
The deal announced on Monday came several days after the World Health Organization declared for the emergency approval of the COVID-19 vaccine formulated by Moderna which paved the way for it to become part of the UN-backed inoculation initiative.
Through this deal, 34 million of the total doses of the Moderna vaccine are going to be delivered within the fourth quarter of2021.
On behalf of the COVAX Facility, Gavi was also given the option to secure about 466 million doses of the vaccine in 2022.
Moderna CEO Stephane Bancel expressed her support for the COVAX initiative, which was co-led by GAVI. She said that this advance purchase agreement is “an important milestone” to ensure that everyone would have secure access to the biotech giant’s vaccine worldwide.
“I am grateful to our Gavi and COVAX partners for their tireless work and to the entire Moderna team for their collaboration to reach this agreement. This is an important milestone as we work to ensure that people around the world have access to our COVID-19 vaccine,” Bancel said in a statement.
“We recognize that many countries have limited resources to access COVID-19 vaccines. We support COVAX’s mission to ensure broad, affordable and equitable access to COVID-19 vaccines and we remain committed to doing everything that we can to ending this ongoing pandemic with our mRNA COVID-19 vaccine.”